Experience with Omalizumab for the treatment of chronic spontaneous urticaria in a tertiary center: real life experience |
| |
| Authors: | Ayda Acar Bengu Gerceker Turk Ilgen Ertam Sagduyu Can Ceylan Gunseli Ozturk Idil Unal |
| |
| Affiliation: | 1. Department of Dermatology and Venereology, Ege University Faculty of Medicine, Izmir, Turkey aydaerbas@yahoo.com!["ORCID]("//:0" "\"ORCID") https://orcid.org/0000-0001-7507-6999;3. Department of Dermatology and Venereology, Ege University Faculty of Medicine, Izmir, Turkey https://orcid.org/0000-0002-3926-4199;4. Department of Dermatology and Venereology, Ege University Faculty of Medicine, Izmir, Turkey https://orcid.org/0000-0003-2341-3935;5. Department of Dermatology and Venereology, Ege University Faculty of Medicine, Izmir, Turkey https://orcid.org/0000-0001-6528-0566;6. Department of Dermatology and Venereology, Ege University Faculty of Medicine, Izmir, Turkey https://orcid.org/0000-0002-9936-4116;7. Department of Dermatology and Venereology, Ege University Faculty of Medicine, Izmir, Turkey https://orcid.org/0000-0002-1639-277X |
| |
| Abstract: | Abstract Purpose Chronic spontaneous urticaria (CSU) is defined as urticaria and/or angioedema that appears spontaneously due to known or unknown causes and lasts for at least 6?weeks. Omalizumab, an anti-IgE antibody that binds circulating free IgE, has recently emerged as a promising treatment for CSU, a condition which impairs patients’ quality of life. We aimed to contribute real life data by reporting our experience with omalizumab in the treatment of intractable CSU. |
| |
| Keywords: | Chronic spontaneous urticaria omalizumab adverse effect relapse remission |
|
|
!["ORCID]({"type":"image","src":"/templates/jsp/images/orcid.png"} "\"ORCID")
https://orcid.org/0000-0001-7507-6999;3. Department of Dermatology and Venereology, Ege University Faculty of Medicine, Izmir, Turkey